fda glp-1 warning letters september 2025 news Beyond the Headlines: to Compounders September 8, 2025: FDA launches

Timeline: When You'll Notice Weight Loss Changes Most patients begin noticing appetite suppression within the first 12 weeks of starting GLP-1 therapy, though visible weight loss typically appears around weeks 36

These are primary risk factors for heart disease and heart attack

Domestic pharmaceutical companies are also entering the incretin drug development field, intensifying competition and accelerating product innovation in the region

Small trials utilizing widely available antihistamine blockers for H1R and H2R in IBD fail to demonstrate clear efficacy, suggesting that they may not be critical in IBD pathogenesis